Literature DB >> 35396319

The Role of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in the Prevention and Treatment of Diabetic Kidney Disease: Insights from the AMPLITUDE-O Trial.

Kalie L Tommerdahl1,2,3, Jessica Kendrick4, Petter Bjornstad5,3,4.   

Abstract

Entities:  

Keywords:  albuminuria; cardiovascular disease; clinical trial; diabetes mellitus; diabetic nephropathy

Mesh：

Substances：

Year:  2022        PMID： 35396319      PMCID： PMC9269664          DOI： 10.2215/CJN.00020122

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  9 in total

1.  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Authors:  Katherine R Tuttle; Mark C Lakshmanan; Brian Rayner; Robert S Busch; Alan G Zimmermann; D Bradley Woodward; Fady T Botros
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-14       Impact factor: 32.069

2.  Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.

Authors:  Carolyn S P Lam; Chinthanie Ramasundarahettige; Kelley R H Branch; Naveed Sattar; Julio Rosenstock; Richard Pratley; Stefano Del Prato; Renato D Lopes; Elisabeth Niemoeller; Nardev S Khurmi; Seungjae Baek; Hertzel C Gerstein
Journal:  Circulation       Date:  2021-11-14       Impact factor: 39.918

Review 3.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

4.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Authors:  Hertzel C Gerstein; Naveed Sattar; Julio Rosenstock; Chinthanie Ramasundarahettige; Richard Pratley; Renato D Lopes; Carolyn S P Lam; Nardev S Khurmi; Laura Heenan; Stefano Del Prato; Leanne Dyal; Kelley Branch
Journal:  N Engl J Med       Date:  2021-06-28       Impact factor: 91.245

5.  A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.

Authors:  Tito Borner; Evan D Shaulson; Ian C Tinsley; Lauren M Stein; Charles C Horn; Matthew R Hayes; Robert P Doyle; Bart C De Jonghe
Journal:  Diabetes Obes Metab       Date:  2020-06-25       Impact factor: 6.577

Review 6.  Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity.

Authors:  Ananthi Anandhakrishnan; Márta Korbonits
Journal:  World J Diabetes       Date:  2016-12-15

7.  Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.

Authors:  Suetonia C Palmer; Britta Tendal; Reem A Mustafa; Per Olav Vandvik; Sheyu Li; Qiukui Hao; David Tunnicliffe; Marinella Ruospo; Patrizia Natale; Valeria Saglimbene; Antonio Nicolucci; David W Johnson; Marcello Tonelli; Maria Chiara Rossi; Sunil V Badve; Yeoungjee Cho; Annie-Claire Nadeau-Fredette; Michael Burke; Labib I Faruque; Anita Lloyd; Nasreen Ahmad; Yuanchen Liu; Sophanny Tiv; Tanya Millard; Lucia Gagliardi; Nithin Kolanu; Rahul D Barmanray; Rita McMorrow; Ana Karina Raygoza Cortez; Heath White; Xiangyang Chen; Xu Zhou; Jiali Liu; Andrea Flores Rodríguez; Alejandro Díaz González-Colmenero; Yang Wang; Ling Li; Surya Sutanto; Ricardo Cesar Solis; Fernando Díaz González-Colmenero; René Rodriguez-Gutierrez; Michael Walsh; Gordon Guyatt; Giovanni F M Strippoli
Journal:  BMJ       Date:  2021-01-13

8.  Diabetic kidney disease: a report from an ADA Consensus Conference.

Authors:  Katherine R Tuttle; George L Bakris; Rudolf W Bilous; Jane L Chiang; Ian H de Boer; Jordi Goldstein-Fuchs; Irl B Hirsch; Kamyar Kalantar-Zadeh; Andrew S Narva; Sankar D Navaneethan; Joshua J Neumiller; Uptal D Patel; Robert E Ratner; Adam T Whaley-Connell; Mark E Molitch
Journal:  Diabetes Care       Date:  2014-10       Impact factor: 19.112

9.  Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial.

Authors:  Lennart Tonneijck; Mark M Smits; Marcel H A Muskiet; Trynke Hoekstra; Mark H H Kramer; A H Jan Danser; Michaela Diamant; Jaap A Joles; Daniël H van Raalte
Journal:  Diabetologia       Date:  2016-04-01       Impact factor: 10.122
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.